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An increasing body of evidence implicates proinflammatory cytokines in psychiatric disorders, namely, in depression. Of notice,
recent studies showed that anti-inflammatory cytokines, such as IL-10, also modulate depressive-like behavior. In this article,
we propose that the anti-inflammatory cytokine IL-10 is a putative link between two of the most widely reported phenomenon
observed in depressed patients: the disruption of the hypothalamic-pituitary-adrenal axis and the imbalanced production of
cytokines. If so, IL-10 might represent a novel target for antidepressant therapy.
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1. Introduction
The establishment of a bidirectional interaction between the
immune and central nervous systems is one of the most
remarkable findings of the last decades. These two systems
accomplish extremely diﬀerent functions, but a growing
body of evidence shows that both share common mediators,
including cytokines and their receptors. Therefore, the
altered expression of these molecules, triggered by one of the
systems, might influence the other in a reciprocal way [1].
As a consequence, a disruption in this cross-talk has been
causally implicated in neuropathological features associated
with several psychiatric disorders, in particular depression
[2].
Major depression is a global public-health problem
and a leading cause of disability worldwide, representing
the fourth contributor to the global burden of disease in
2000 (in terms of DALYs-Disability Adjusted Life Years)
[3]. Depression is a heterogeneous disorder with a variable
set of symptoms, diverse disease courses, and inconsistent
responses to treatment. The etiology of depression is still
controversial, and several theories have emerged to explain
it. Taking into account the communication between the
immune and central nervous systems, Smith, in the early
1990s, proposed a role for cytokines in depression [4].
The “cytokine theory of depression”, that has been widely
studied in the last two decades, proposes that enhanced
production of proinflammatory cytokines is associated with
the pathogenesis of depression. Indeed, several studies show
a significant increase in the production of proinflammatory
cytokines (namely, IL-6, IL-1β, IFN-γ, and TNF) among
depressed patients [5–8]. Moreover, immunotherapy based
on the administration of IFN-α and IL-2, which is frequently
used as part of the treatment against chronic hepatitis C and
certain cancers, has been associated with depressed mood
and symptoms of cognitive impairment and fatigue [8–
10]. The fact that the symptoms associated with depression
disappear almost immediately after termination of cytokine
administration supports a causal role for cytokines in the
disease; moreover, these symptoms can also be relieved by
the administration of antidepressant drugs [11].
The “cytokine theory of depression” has also been
supported by a large set of results in animals models.
Research using these models demonstrated that alteration in
the proinflammatory cytokine milieu can lead to behavioral
changes overlapping with those found in depressed patients,
including anhedonia, decreased activity, cognitive dysfunc-
tion, and altered sleep patterns [12]. In further support of
this link, mice exposed to a chronic mild stress (CMS) pro-
tocol, which induces symptoms of depressive-like behavior,
show increased levels of IL-1 in the hippocampus [13]. Fur-
thermore, the depressive-like behavior observed after CMS
can be mimicked by chronic administration of IL-1 [13]
and, when mice lacking the expression of IL-1 receptor are
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exposed to the same CMS paradigm, the behavioral changes
do not occur [13]. Interestingly, mice unable to express the
receptor for TNF, one of the cytokines more consistently
upregulated in depression, show decreased immobility in the
forced swim test (FST), that is, decreased signs of depressive-
like behavior in a test that assesses learned helplessness and is
considered one of the gold standard tests to evaluate depres-
sion in rodents [14]. These observations suggest that TNF
activation also mediates depressive-like behavior in mice.
Although most studies on the “cytokine theory of
depression” are centered on increased levels of proinflam-
matory cytokines, the role of anti-inflammatory cytokines
has been recently analyzed. Of notice, IL-10, one of the
most important anti-inflammatory cytokines, proved to be
relevant in depression [15]. Specifically, mice lacking the
expression of IL-10 (IL-10KO) show a decreased latency to
immobility and longer immobilization time than wild-type
(WT) mice in the FST [15]. These results demonstrate that
IL-10KO mice display increased helplessness, a recognized
sign of depressive-like behavior in rodents. Remarkably,
administration of IL-10 is able to revert the depressive-like
phenotype observed in the IL-10KO animals [15]. In further
support of a role for IL-10 in depression, transgenic mice
overexpressing this cytokine show a decreased depressive-
like behavior in the FST in comparison with WT animals
[15]. In addition to the increased helplessness in mice that
lack the expression of IL-10, other studies also reported that
modulation of IL-10 impacts on psychophysiological alter-
ations frequently observed in depression. Among these is the
impairment in sleep behavior [16]. Interestingly, IL-10KO
mice show alterations in the sleep pattern, and the exogenous
administration of IL-10 modulates sleep behavior [17–19].
Another feature commonly associated with depression is
altered pain perception [20]. Tu and coworkers described,
using the IL-10KO mouse model, that the absence of this
anti-inflammatory cytokine is associated with decreased
nociception (i.e., the ability to sense painful stimuli). This
study showed that IL-10KO mice have an increased latency
time to paw licking (the time that mice spend to avoid a
heat stimulus by moving away and lick the paw) compared
with WT mice, and this result was confirmed by the blockage
of IL-10 in WT mice [21]. This constitutes an additional
evidence that IL-10 can also be involved in the common
biological pathways shared by pain and depression.
The studies described above show that modulation of IL-
10 impacts on several symptoms associated with depression,
namely, helplessness, sleep disturbances, and pain percep-
tion. Noticeable, administration of IL-10 can modulate these
symptoms which suggests a putative antidepressant eﬀect of
the anti-inflammatory cytokine IL-10. Of relevance for this
hypothesis is the observation, in depressed patients and also
in animalmodels of depression, of increased IL-10 levels after
treatment with several classes of antidepressants [22–25].
Although it is becoming clear that modulation of IL-10
can lead to changes in the normal behavior of humans and
animals, the mechanisms behind these alterations remain to
be elucidated. One might envisage several pathways through
which IL-10 influences behavior. One of the most obvious
hypotheses is the impact this anti-inflammatory cytokine
may have on the levels of proinflammatory cytokines. In
fact, it is admissible that the absence of IL-10, in IL-10KO
mice, leads to an increased production of proinflammatory
cytokines that could, in accordance with the “cytokine theory
of depression”, trigger depression. This mechanism could
also explain the abrogation of the depressive-like behavior
in IL-10KO mice upon IL-10 administration [15], as IL-
10 is known to inhibit the expression of proinflammatory
cytokines [26]. However, this possibility is not supported by
our results, as we were unable to detect two of the most
relevant proinflammatory cytokines (IFN-γ and TNF) in
the serum of IL-10KO mice [15]. More studies are certainly
necessary to clearly define how the lack of IL-10 impacts on
the production of proinflammatory cytokines as it is possible
that subtle (below currently detection limits) changes in the
concentration of these cytokines are present in the serum of
IL-10KO mice, and/or that the absence of IL-10 induces the
upregulation of proinflammatory cytokines in specific brain
regions, which may not be reflected in the serum.
The observations that systemic IL-10 administration to
WT animals induces alterations in their normal behavior
(e.g., increased motor activity and abnormal exploratory
patterns) [27] and that the same protocol reverts the
depressive-like behavior observed in IL-10KO mice [15]
indicate that peripheral IL-10 has an eﬀect in the central
nervous system. However, it is not clear how this cytokine
acts within the central nervous system particularly since
peripheral IL-10 does not seem to cross the intact blood-
brain barrier, at least in detectable amounts [28]. It is
possible that IL-10, like other cytokines, acts directly in the
brain through regions devoided of blood-brain barrier, such
as the circumventricular organs and the choroid plexus, or
by activating vagal aﬀerent fibers that can transmit cytokine
signals to specific brain nuclei [5]. Moreover, IL-10 has been
detected in normal human, rat, and mouse brains [29].
Possible sites of expression are the endothelial cells of the
brain capillaries that irrigate the brain, the choroid plexus
(from where it would be secreted into the cerebrospinal
fluid), and also microglia and astrocytes [29–31]. Of interest,
a recent study showed that several immune mediators are
produced by the choroid plexus in response to systemic
inflammatory stimuli [32]. In addition, the IL-10 receptor
has been indentified in microglia, astrocytes [29, 30], and
oligodendrocytes [29, 30, 33]; probably because of a general
distribution, Ward and coworkers found expression of the
receptor in all five brain regions they analyzed (cortex, cere-
bellum, hippocampus, hypothalamus, and pituitary) [34].
A direct action of IL-10 within the central nervous system
might be mediated by its role in regulating cell survival. IL-
10 has been shown to prevent cell death of glial cells [33,
35, 36] and to increase survival of cerebellar neurons [37].
Since an increase in neuronal apoptosis in the hippocampus
has been associated with depression in animal models [38],
this putative role of IL-10 in increasing neuronal survival
should be investigated as a potential mechanisms of action
in preventing depressive-like behavior.
The observation that IL-10KO mice show an increase in
the adrenal and a decrease in the thymus relative weights
[15] oﬀers another alternative mechanism for the action of

























Figure 1: Schematic representation of the link between IL-10 and HPA axis. (a) in a basal situation and (b) during depression.
IL-10 in depression: the modulation of the hypothalamic-
pituitary-adrenal (HPA) axis. Indeed, it was shown that,
even in basal conditions, IL-10KO mice have higher levels
of corticosterone and that in the presence of a stressor the
increase of this hormone is even more accentuated than in
WT mice [39]. These findings strongly suggest that IL-10
may have a regulatory eﬀect in the HPA axis. One of the most
consistent neurobiological alterations in depressed subjects
is the hyperactivity of the HPA axis which is associated
with impaired HPA axis glucocorticoid feedback sensitivity
(glucocorticoid resistance) [40]. Thus, it is plausible that IL-
10 modulation of depressive-like behavior is exerted through
regulation of the HPA axis. In accordance, IL-10 is able to
suppress, in a dose dependent manner, adrenocorticotropic
hormone-(ACTH-) induced steroid production in adrenal
cells [41]. This eﬀect appears to be exerted through downreg-
ulation of enzymes responsible for the biosynthetic pathway
of corticosterone [21, 41]. Interestingly, IL-10 receptor was
shown to be expressed in the zona fasciculata (the region
responsible for the production of glucocorticoids) of the
mouse adrenal gland [41]. Accordingly, in vivo studies
demonstrated that, under basal conditions, IL-10KO mice
have clear signs of HPA axis activation, such as increased
adrenal glands, decreased thymus relative weight, and higher
levels of corticosterone [15, 39]. These findings strongly
suggest that IL-10 exerts a negative regulation on corticos-
terone production by the adrenal gland [41]. A microarray
analysis of adrenal, pituitary, and hypothalamic neural cells
treated with IL-10 clearly showed that this anti-inflammatory
cytokine plays a pivotal role in the regulation of several
genes of the HPA axis [42]. Of notice, murine pituitary
cells were the first identified nonimmune-related sources of
IL-10 [43], and the presence of IL-10 was also found in
human pituitary [44]. Paradoxically, in the hypothalamus
and pituitary, IL-10 seems to have the same eﬀect already
described for some proinflammatory cytokines [45], which
is a positive regulation of corticotrophin releasing factor
(CRF) and ACTH production, respectively [43, 46]. It should
be noticed that while the studies in the hypothalamus and
pituitary were only performed in vitro, the inhibitory action
of IL-10 in corticosterone production by the adrenal gland
is a more consistent result as it is based on in vitro and in
vivo studies. Taking into account that depression is often
associated with hyperactivity of the HPA axis [40], we
hypothesize that IL-10 has a pivotal role in the modulation of
the HPA axis homeostasis, which is likely to have an impact
on the etiology of depression.
Increases in glucocorticoid levels can occur daily in
response to several factors. This glucocorticoid increase
leads to an enhanced production of IL-10 [47] which, in
normal situations, together with glucocorticoids, inhibits the
activity of the HPA axis (Figure 1(a)). However, if these
raises in glucocorticoid levels become too frequent, cells
might develop “resistance to glucocorticoid action” [40, 48].
In fact, impaired negative feedback regulation of HPA axis
function is a hallmark of major depression and is reflected by
decreased responsiveness to glucocorticoids [40]. Of notice,
resistance to glucocorticoids was also described in IL-10
producing cells [48]. The glucocorticoid resistance leads to
a decrease in the production of IL-10 which might impact on
the negative regulation of corticosterone production by the
adrenal glands. In addition, decreased IL-10 can promote an
imbalance in the cytokine milieu that would further activate
the HPA axis (Figure 1(b)). This hypothesis fits well with the
observations that, in certain circumstances, glucocorticoids
trigger a proinflammatory action [49].
In the hypothesis outlined here we proposed IL-10
as an important link between the changes in hormonal
4 Cardiovascular Psychiatry and Neurology
and cytokine milieus that are of recognized relevance
for depression. In the future, studies in molecules that
might represent a link between the modulation of neural,
endocrine, and immune systems are extremely important to
further understand the etiology of depression. The cross-talk
between these systems, mediated by IL-10, may become a
target for novel antidepressant therapies.
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